EUCTR2021-001568-10-ES进行中（未招募）1 期
An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors - A Phase 1b/2 Study: E7386+Pembrolizumab in Treated Cancer Subjects
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female, age =18 years (or any age greater than 18 years as determined by country legislation) at the time of informed consent.
- •- Life expectancy of =12 weeks
- •- Have a histologically or cytologically-documented, advanced (metastatic and/or unresectable) selected solid tumour for which prior standard systemic therapy has failed. Selected tumor types: melanoma (excluding uveal melanoma), CRC, HCC regardless of line of therapy received.
- •Phase 2 (melanoma only)- subject must have:
- •a. Unresectable Stage III or Stage IV melanoma, per American Joint Committee on Cancer staging system version 8, not amenable to local therapy.
- •b. At least one measurable lesion by computer topography (CT) or magnetic resonance imagery (MRI) based on RECIST 1.1 (cutaneous lesions and other superficial lesions are not considered measurable lesions for the purposes of this protocol but may be considered as nontarget lesions). Lesions in a previously irradiated area should not be considered measurable unless there has been documented growth of the lesions since the completion of radiotherapy (please see Amendment 02 for remaining details)
- •For CRC Cohort only (Phase 2 part), subjects must have received at least two prior systemic therapies from the following, in adjuvant and/or metastatic setting, if approved and locally available (not exceeding 4 lines of therapies in the metastatic setting, progressed on at least 1 prior regimen in the metastatic setting or could not tolerate standard treatment):
- •Note: Adjuvant chemotherapy counts as prior systemic treatment in the metastatic setting if there is documented disease progression within 6 months of treatment completion.
- •Note: If a subject is determined to be intolerant to prior standard treatment, the subject must have received at least of 2 cycles of that therapy.
- •PLEASE SEE PROTOCOL FOR FULL DETAILS AND LIST OF INCLUSION CRITERIA
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 54
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 54
排除标准
- •Subjects who meet any of the following criteria will be excluded from this study:
- •1. History of other active malignancy (except for original disease, or definitively treated basal or squamous cell skin carcinoma, carcinoma in-situ of the bladder or cervix) within the past 24 months prior to the first dose of study drug.
- •2. Major surgery within 21 days prior to starting study drug or minor surgery within 1 week (subject must also have recovered from any surgery-related toxicities to less than CTCAE Grade 2).
- •3. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability of E7386 in the opinion of the investigator(s).
- •4. Any of the cardiac conditions as follows:
- •- New York Heart Association (NYHA) congestive heart failure Class II or above
- •- Unstable ischemic heart disease (myocardial infarction within 6 months prior to starting study drug, or angina, other than adequately controlled mild exertional angina.
- •- Serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months
- •- Prolongation of corrected QT (QTcF) interval to >450 msec
- •- Left ventricular ejection fraction (LVEF) <50%
- •5. Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to study drug administration. The subject can receive diuretic drugs as needed per the treating physician, outside of the above-mentioned conditions. Consult with the sponsor if the subject has more than trivial/trace fluid accumulation.
- •6. Prior treatment with E7386, or has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, [CTLA-4], OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related (ir)AE.
- •7. Subjects who have received treatments below before first study drug administration:
- •a. Any prior anticancer treatment: within 4 weeks or 5 times the half-life, whichever is shorter
- •b. Any investigational drug or device: within 4 weeks
- •c. For study drugs in other studies such as mAbs with half-lives >10 days: within 56 days
- •d. Radiotherapy: within 2 weeks of start of study drug. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease.
- •e. Have received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
- •f. Has not recovered adequately from the toxicity and/or complications from the intervention if subject received major surgery prior to starting study drug.
- •g. Drugs or supplements that are known potent cytochrome P450 3A (CYP3A) inducers/inhibitors or substrates with narrow therapeutic indices within 4 weeks before study drug administration.
- •PLEASE SEE PROTOCOL FOR FULL DETAILS AND LIST OF EXCLUSION CRITERIA
研究者
相似试验
招募中
1 期
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumorsmetastatic or unresectable melanoma, metastatic or unresectable hepatocellular carcinoma, metastaticJPRN-jRCT2031210405Tamai Toshiyuki108
进行中（未招募）
1 期
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumorscolorectal cancer, hepatocellular carcinoma, melanomaMedDRA version: 20.0Level: PTClassification code: 10073071Term: Hepatocellular carcinoma Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10061451Term: Colorectal cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10053571Term: Melanoma Class: 10029104CTIS2023-505425-14-00Eisai Limited105
进行中（未招募）
1 期
An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone.nresectable Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 18.0Level: PTClassification code 10038414Term: Renal cell carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019484-10-PLEisai Ltd150
进行中（未招募）
1 期
An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone.EUCTR2010-019484-10-ESEisai Ltd178
进行中（未招募）
1 期
An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone.nresectable Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10038414Term: Renal cell carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019484-10-CZEisai Ltd150